Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Nuclear factor-kappaB (NF-ĸB) plays a crucial role in both innate and adaptive immune
systems, significantly influencing various physiological processes such as cell proliferation …

Gemcitabine resistance is a major obstacle to the effectiveness of chemotherapy in
pancreatic ductal adenocarcinoma (PDAC). Therefore, new strategies are needed to …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver
mutations have now changed the course of lung cancer treatment with the emergence of …

Acquired resistance is inevitable in the treatment of non-small cell lung cancer (NSCLC) with
osimertinib, and one of the primary mechanisms responsible for this resistance is the …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …

The acquired resistance to Osimertinib (AZD9291) greatly limits the clinical benefit of
patients with non‐small cell lung cancer (NSCLC), whereas AZD9291‐resistant NSCLCs …

The development of tumor therapeutic resistance is one of the important reasons for the
failure of antitumor therapy. Starting with multiple targets and multiple signaling pathways is …

Simple Summary The study discusses the potential of targeting transcription factors (TFs) for
cancer therapy and provide a systematic classification of various types of TFs involved in the …